AbbVie Inc. and Johnson & Johnson, latest fiscal year, normalized from SEC EDGAR — every value links to the filing it came from.
| ABBV | JNJ | |
|---|---|---|
| Revenue | $61.16B FY2025 | $94.19B FY2025 |
| Net income | $4.23B FY2025 | $26.8B FY2025 |
| Net margin | 6.9% FY2025 | 28.5% FY2025 |
| Free cash flow | $17.82B FY2025 | $19.7B FY2025 |
| Total assets | $133.96B FY2025 | $199.21B FY2025 |
| Shareholders' equity | $-3.27B FY2025 | $81.54B FY2025 |
| Diluted EPS | $2.36 FY2025 | $11.03 FY2025 |